CTOs on the Move

Twist Bioscience

www.twistbioscience.com

 
Twist Bioscience is a synthetic biology company based in San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Siyuan Chen
Chief Technology Officer Profile
Chet Gandhi
Chief Information Officer Profile
Patrick Weiss
Senior Vice President of Research and Development and General Manager of Data Storage Profile

Jobs

Vice President Human Resources

Twist Bioscience San Francisco, CA
The Vice President of Human Resources will lead all HR related activities for the company. As a member of the leadership team s/he will work closely with the team to align the HR agenda with the growth and strategic objectives for the company. The ideal candidate will be a creative, ...

Funding

Twist Bioscience raised $61M on 01/19/2016
Twist Bioscience raised $33M on 03/27/2017
Twist Bioscience raised $166.11M on 03/28/2017
Twist Bioscience raised $50M on 03/31/2018

Similar Companies

AmacaThera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Eurofins Genomics

Eurofins Genomics is an international provider of DNA sequencing services, oligonucleotide synthesis products and bioinformatic services. The company’s strength is its strong customer orientation, fast service and high quality products including a seri...

Cullgen

Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.

Myriant Technologies

At Myriant, we know there`s a better, greener way to produce the products people use every day. And we`re realizing that vision—displacing barrels of petroleum by manufacturing and selling high-value chemicals made from renewable, sustainable feedstocks. As companies and consumers look for ways to reduce their carbon footprint and transition away from petroleum`s price volatility, Myriant has the solution: our proven technology platform and strategic feedstock selection enable Myriant to deliver high-quality, high-performing, green chemicals at a competitive, more-predictable cost versus petroleum-based chemicals without the need for government subsidies. That`s what we call a sustainable advantage.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.